Drugs for Breast Cancer

Table. Drugs Prescribed for Breast Cancer

• Drug name (generic name)
• Drug company
• Indications
• Patient support services

Drug name (generic name)
• Abraxane (paclitaxel protein-bound particles; albumin-bound)
Drug company
• Bristol Myers Squibb
Indication
• Metastatic breast cancer after failure of chemotherapy
Patient support services
• BMS Oncology Co-Pay Assistance Program
  800-861-0048
  
  Bristol Myers Squibb Patient Assistance Foundation
  800-736-0003

Drug name (generic name)
• Afinitor (everolimus) Tablets
Drug company
• Novartis
Indications
• Postmenopausal women with advanced HR-positive, HER2-negative breast cancer, in combination with Aromasin
Patient support services
• Novartis Oncology Universal Co-Pay Program
  877-577-7756
  
  Novartis Patient Assistance Foundation
  800-277-2254

Drug name (generic name)
• Arimidex (anastrozole) Tablets
Drug company
• ANI Pharmaceuticals
Indications
• Postmenopausal, HR-positive early breast cancer
  
  First-line treatment of postmenopausal HR-positive or HR-unknown, locally advanced or metastatic breast cancer
  
  Second-line treatment of postmenopausal advanced breast cancer after Nolvadex or Soltamox therapy
Patient support services
• Arimidex Patient Direct Program
  855-250-2483

Drug name (generic name)
• Aromasin (exemestane) Tablets
Drug company
• Pfizer
Indications
• Postmenopausal ER-positive early breast cancer
  
  Postmenopausal advanced breast cancer, after Nolvadex or Soltamox therapy
Patient support services
• Pfizer Patient Assistance Program
  877-744-5675

Drug name (generic name)
• Ellence (epirubicin hydrochloride) Injection
Drug company
• Pfizer
Indications
• Axillary node tumor, after resection of primary breast cancer
Patient support services
• Pfizer Patient Assistance Program
  877-744-5675

Drug name (generic name)
• Enhertu (fam-trastuzumab) Injection
Drug company
• Daiichi Sankyo and AstraZeneca
Indications
• Treatment of adults with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ ISH‑) breast cancer who have received chemotherapy for metastatic disease or disease recurrence during or within 6 months of completing adjuvant chemotherapy
Patient support services
• Enhertu Patient Savings Program
  833-364-3788
  
  Enhertu Patient Assistance Program
  833-364-3788

Drug name (generic name)
• Fareston (toremifene citrate) Tablets
Drug company
• Kyowa Kirin
Indication
• Metastatic breast cancer in postmenopausal women with ER-positive or unknown tumors
Patient support services
• Fareston Copay Assistance Card Program
  844-214-3442
  
  Fareston Patient Assistance Program
  844-214-3442

Drug name (generic name)
• Faslodex (fulvestrant)
Drug company
• AstraZeneca
Indication
• First-line treatment of HRpositive, HER2-negative advanced breast cancer in postmenopausal women who have not received endocrine therapy
  
  HR-positive metastatic breast cancer in postmenopausal women, after anti-estrogen therapy
  
  HR-positive, HER2-negative advanced or metastatic breast cancer, in combination with Ibrance or with Verzenio
Patient support services
• FASLODEX Co-pay Savings Program
  844-275-2360
  
  AZ&Me Prescription Savings Program
  844-275-2360

Drug name (generic name)
• Halaven (eribulin mesylate) Injection
Drug company
• Eisai
Indications
• Metastatic breast cancer, after chemotherapy and an anthracycline and a taxane therapy
Patient support services
• Halaven $0 Co-Pay Program
  866-613-4724
  
  Halaven Patient Assistance Program
  866-613-4724

Drug name (generic name)
• Herceptin (trastuzumab)
Drug company
• Genentech
Indications
• HER2-overexpressing breast cancer
Patient support services
• Genentech Oncology Co-pay Assistance Program
  855-692-6729
  
  Genentech Patient Foundation
  888-941-3331

Drug name (generic name)
• Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) Injection
Drug company
• Genentech
Indications
• Adjuvant treatment of HER2-positive breast cancer, in combination with chemotherapy, or alone after multiple anthracycline-based therapies
  
  Treatment of HER2-positive metastatic breast cancer, after 1 or more chemotherapies for metastatic disease
Patient support services
• Genentech Oncology Co-pay Assistance Program
  855-692-6729
  
  Genentech Patient Foundation
  888-941-3331

Drug name (generic name)
• Ibrance (palbociclib) Capsules/Tablets
Drug company
• Pfizer
Indications
• Treatment of HR-positive, HER2-negative advanced or metastatic breast cancer, in combination with an aromatase inhibitor as initial endocrine-based therapy, in postmenopausal women, or in men
  
  Treatment of HR-positive, HER2-negative advanced or metastatic breast cancer, in combination with fulvestrant, in adults whose disease progressed after endocrine therapy
Patient support services
• Pfizer Oncology Together Co-Pay Savings Program
  877-744-5675
  
  Pfizer Patient Assistance Program
  877-744-5675

Drug name (generic name)
• Ixempra (ixabepilone)
Drug company
• R-Pharm US
Indications
• Metastatic or locally advanced breast cancer, in combination with Xeloda
  
  Metastatic or locally advanced breast cancer, after failure of an anthracycline, a taxane, and Xeloda
Patient support services
• R-Pharm US Access + Support Program
  855-991-7277

Drug name (generic name)
• Kadcyla (ado-trastuzumab emtansine)
Drug company
• Genentech
Indication
• HER2-positive metastatic breast cancer, after Herceptin and/or a taxane
  
  Adjuvant treatment of HER2-positive early breast cancer in patients with residual invasive disease, after neoadjuvant taxane and trastuzumab-based treatment
Patient support services
• Genentech Oncology Co-pay Assistance Program
  855-692-6729
  
  Genentech Patient Foundation
  888-941-3331

Drug name (generic name)
• Kanjinti (trastuzumab-anns) Injection
Drug company
• Amgen
Indications
• Treatment of HER2-overexpressing breast cancer
Patient support services
• Amgen FIRST STEP Co-Pay Program
  866-264-2778
  
  Amgen Safety Net Foundation
  866-264-2778

Drug name (generic name)
• Keytruda (pembrolizumab)
Drug company
• Merck
Indications
• Treatment, in combination with chemotherapy, of patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors express PD-L1, as determined by an FDA-approved test
  
  Treatment of patients with highrisk, early-stage, triple-negative breast cancer, in combination with chemotherapy as neoadjuvant treatment, and then continued alone as adjuvant treatment after surgery
Patient support services
• Merck Co-pay Assistance Program
  855-257-3932
  
  Merck Patient Assistance Program
  855-257-3932

Drug name (generic name)
• Kisqali (ribociclib) Tablets
Drug company
• Novartis
Indications
• Treatment of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, in combination with an aromatase inhibitor
  
  Treatment, in combination with Faslodex, of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrinebased therapy or after disease progression with endocrine therapy
Patient support services
• Kisqali Free Treatment Voucher
  877-744-5675
  
  Kisqali 5-Treatment Cycle Access Program
  800-282-7630
  
  Novartis Oncology Universal Co-pay Program
  877-577-7756
  
  Novartis Patient Assistance Foundation
  800-277-2254

Drug name (generic name)
• Lynparza (olaparib) Capsules/Tablets
Drug company
• AstraZeneca
Indications
• Treatment of deleterious or suspected deleterious germline BRCA mutation-positive, HER2- negative metastatic breast cancer, after chemotherapy
  
  Adjuvant treatment of adults with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy. Patients must be selected for therapy based on an FDA-approved companion diagnostic for olaparib
Patient support services
• Lynparza Co-pay Savings Program
  844-275-2360
  
  AZ&Me Prescription Savings Program
  800-292-6363
  

Drug name (generic name)
• Margenza (margetuximab-cmkb) Injection
Drug company
• MacroGenics
Indications
• Treatment, in combination with chemotherapy, of adults with metastatic HER2-positive breast cancer who have received 2 or more previous anti-HER2 regimens, at least 1 of which was for metastatic disease
Patient support services
• Margenza Copay Assistance Program
  844-633-6469
  
  Margenza Patient Assistance Program
  844-633-6469
  

Drug name (generic name)
• Nerlynx (neratinib) Tablets
Drug company
• Puma Biotechnology
Indications
• Treatment, in combination with Xeloda, of adults with advanced or metastatic HER2-positive breast cancer who have received 2 or more previous anti-HER2 regimens for metastatic disease
Patient support services
• Puma Patient Lynx Co-pay Savings Program
  855-816-5421
  
  Nerlynx Patient Assistance Program
  855-816-5421
  
  Nerlynx Quick Start Program
  855-816-5421

Drug name (generic name)
• Ogivri (trastuzumab-dkst) Injection
Drug company
• Mylan
Indications
• Treatment of HER2-overexpressing breast cancer
Patient support services
• Mylan Advocate Co-Pay Assistance Program
  833-695-2623
  
  Mylan Advocate Patient Assistance
  833-695-2623

Drug name (generic name)
• Ontruzant (trastuzumab-dttb) Injection
Drug company
• Organon
Indications
• First-line treatment, in combination with paclitaxel, of HER2-overexpressing metastatic breast cancer
  
  Treatment of HER2- overexpressing breast cancer in patients who have received 1 or more chemotherapy regimens for metastatic disease
Patient support services
• Organon Co-pay Assistance Program
  844-326-2986
  
  Organon Patient Assistance Program
  844-326-2986

Drug name (generic name)
• Perjeta (pertuzumab)
Drug company
• Genentech
Indications
• HER2-positive metastatic breast cancer, in combination with Herceptin and Taxotere
  
  Neoadjuvant treatment for HER2-positive, locally advanced, inflammatory, or early-stage breast cancer, in combination with Herceptin and Taxotere
Patient support services
• Genentech Oncology Co-pay Assistance Program
  855-692-6729
  
  Genentech Patient Foundation
  888-941-3331

Drug name (generic name)
• Phesgo (pertuzumab, trastuzumab + hyaluronidase-zzxf) Injection
Drug company
• Genentech
Indications
• Neoadjuvant treatment, in combination with chemotherapy, of patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer
  
  Adjuvant treatment of patients with HER2-positive early-stage breast cancer at high risk of recurrence
  
  Treatment, in combination with docetaxel, of patients with HER2-positive metastatic breast cancer who have not received anti-HER2 therapy or chemotherapy for metastatic disease
Patient support services
• Genentech Oncology Co-pay Assistance Program
  855-692-6729
  
  Genentech Patient Foundation
  888-941-3331

Drug name (generic name)
• Piqray (alpelisib) Tablets
Drug company
• Novartis
Indications
• Treatment of postmenopausal women, and men, with HR-positive, HER2-negative advanced or metastatic breast cancer and PIK3CA mutation, whose disease progressed during or after endocrine therapy, in combination with fulvestrant
Patient support services
• Novartis Oncology Universal Co-pay Program
  877-577-7756
  
  Free Trial Program and Access Program
  800-282-7630
  
  Novartis Patient Assistance Foundation
  800-277-2254

Drug name (generic name)
• Talzenna (talazoparib) Capsules
Drug company
• Pfizer
Indications
• HER2-negative locally advanced or metastatic breast cancer with germline BRCA mutations
Patient support services
• Pfizer Oncology Together Co-Pay Savings Card
  877-744-5675
  
  Pfizer Patient Assistance Program
  877-744-5675

Drug name (generic name)
• Tecentriq (atezolizumab)
Drug company
• Genentech
Indications
• Treatment, in combination with Abraxane, of unresectable, locally advanced or metastatic triple-negative breast cancer expressing PD-L1, as determined by an FDA-approved test
Patient support services
• Genentech Oncology Co-pay Assistance Program
  855-692-6729
  
  Genentech Patient Foundation
  888-941-3331

Drug name (generic name)
• Trazimera (trastuzumab-qyyp)
Drug company
• Pfizer
Indications
• Adjuvant treatment, in combination with various chemotherapy regimens, of patients with HER2-overexpressing node-positive or node-negative breast cancer
  
  Treatment of HER2-overexpressing breast cancer as a single agent, after anthracycline-based therapy
  
  First-line treatment, in combination with paclitaxel, of HER2-overexpressing metastatic breast cancer
  
  Treatment of HER2-overexpressing metastatic breast cancer in patients who have received 1 or more chemotherapy regimens for metastatic disease
Patient support services
• Pfizer Oncology Together Co-Pay Savings Program
  877-744-5675
  
  Pfizer Patient Assistance Program
  877-744-5675

Drug name (generic name)
• Trodelvy (sacituzumab govitecan-hziy) Injection
Drug company
• Gilead
Indications
• Treatment of adults with metastatic triple-negative breast cancer who have received at least 2 previous therapies for metastatic disease
Patient support services
• Trodelvy Savings Program
  844-876-3358
  
  Gilead Patient Assistance Program
  844-876-3358

Drug name (generic name)
• Tukysa (tucatinib) Tablets
Drug company
• Seagen
Indications
• Treatment of adults with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received 1 or more previous anti-HER2 regimens for metastatic disease
Patient support services
• Commercial Out-of-Pocket Assistance Program
  855-473-2873
  
  Patient Assistance Program
  855-473-2873

Drug name (generic name)
• Tykerb (lapatinib) Tablets
Drug company
• Novartis
Indications
• Advanced or metastatic breast cancer overexpressing HER2, in combination with Xeloda, after an anthracycline, a taxane, and Herceptin
  
  Postmenopausal, HR-positive metastatic breast cancer overexpressing HER2, in combination with Femara
Patient support services
• Novartis Oncology Universal Co-pay Program
  877-577-7756
  
  Novartis Patient Assistance Foundation
  800-277-2254

Drug name (generic name)
• Verzenio (abemaciclib) Tablets
Drug company
• Eli Lilly
Indication
• Adjuvant treatment, in combination with endocrine therapy, tase inhibitor) of adults with HR-positive, HER2-negative, node-positive, early breast cancer at high risk of recurrence and a Ki-67 score at least 20%, as determined by an FDA-approved test
  
  As initial endocrine-based treatment, in combination with an aromatase inhibitor, of postmenopausal women, and men, with HR-positive, HER2-negative advanced or metastatic breast cancer
  
  Treatment, in combination with fulvestrant, of adults with HR-positive, HER2-negative advanced or metastatic breast cancer that has progressed after endocrine therapy
  
  Treatment (alone) of adults with HR-positive, HER2-negative advanced or metastatic breast cancer that progressed after endocrine therapy and before chemotherapy in the metastatic setting
Patient support services
• Verzenio Continuous Care Program
  844-837-9364
  
  Verzenio Savings Card
  844-837-9364

Drug name (generic name)
• Xeloda (capecitabine) Tablets
Drug company
• Genentech
Indications
• Metastatic breast cancer, in combination with Taxotere, after failure of anthracyclinecontaining therapy
Patient support services
• Genentech Patient Foundation
  888-941-3331

Drug name (generic name)
• Zoladex (goserelin) Implant
Drug company
• TerSera Therapeutics
Indication
• Palliative treatment, in combination with flutamide, of premenopausal or perimenopausal women with advanced breast cancer
Patient support services
• Zoladex Copay Card
  844-864-3014
  
  Zoladex Patient Assistance Program
  855-686-8725